Indications and uses
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies: runny nose sneezing itchy, watery eyes itching of the nose or throat
adults and children 6 years and over one 10 mg capsule once daily; do not take more than one 10 mg capsule in 24 hours. A 5 mg product may be appropriate for less severe symptoms. adults 65 years and over ask a doctor children under 6 years of age ask a doctor consumers with liver or kidney disease ask a doctor
store at 20°-25°C (68°-77°F) avoid high humidity and excessive heat above 40°C (104°F) protect from light do not use if foil inner seal printed with "SAFETY SEAL®" is broken or missing
Drug Facts
Cetirizine HCl 10 mg
Antihistamine
temporarily relieves these symptoms due to hay fever or other upper respiratory allergies:
Do not use if you have ever had an allergic reaction to this product or any of its ingredients or to an antihistamine containing hydroxyzine.
Ask a doctor before use if you have liver or kidney disease.
Your doctor should determine if you need a different dose.
Ask a doctor or pharmacist before use if you are taking tranquilizers or sedatives.
Stop use and ask a doctor if an allergic reaction to this product occurs. Seek medical help right away.
Keep out of reach of children. In case of overdose, get medical help or contact a Poison Control Center right away. (1-800-222-1222)
| adults and children 6 years and over | one 10 mg capsule once daily; do not take more than one 10 mg capsule in 24 hours. A 5 mg product may be appropriate for less severe symptoms. |
| adults 65 years and over | ask a doctor |
| children under 6 years of age | ask a doctor |
| consumers with liver or kidney disease | ask a doctor |
gelatin, glycerin, mannitol, pharmaceutical ink, polyethylene glycol 400, purified water, sodium hydroxide, sorbitan, sorbitol
call 1-800-343-7805 (toll-free) or 215-273-8755 (collect)
Original Prescription Strength
NDC 50580-779-12
ZYRTEC
®
ALLERGY
INDOOR + OUTDOOR
ALLERGIES
Cetirizine HCl/
antihistamine
10 mg capsules
LIQUID
GELS
24
HOUR
RELIEF OF
(Actual Size)
12
LIQUID GELS*
*LIQUID-FILLED CAPSULES
10 mg each

| Product concept | Relation | Version | Effective |
|---|---|---|---|
| c505bb17-4ff9-45f9-ac2d-bb9c8c9d35be | Product name | 1 | 20200304 |
| a255659f-db40-429d-8c07-5f173f330d9c | Product name | 1 | 20190402 |
| Package NDC | Billing unit | Product NDC | DailyMed indexing SPL | SPL version | Effective |
|---|---|---|---|---|---|
| 50580-779-12 | EA - Each | 50580-779 | 55b1fc91-dfc4-4ca8-a5a1-405e3b8597d5 | 1 | 2012-07-24 |
| 50580-779-25 | EA - Each | 50580-779 | 59492dd0-fb59-4646-b8f9-a56adc90fa01 | 1 | 2012-07-24 |
| 50580-779-40 | EA - Each | 50580-779 | 3e06abb1-99ed-408a-8c0e-493ed2211462 | 1 | 2012-07-24 |
| 50580-779-65 | EA - Each | 50580-779 | 35e610c2-8d04-4dbc-b125-36130d203206 | 1 | 2012-07-24 |
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| Cetirizine Hydrochloride | ACTIVE INGREDIENT | 64O047KTOA | 4 | |
| Cetirizine | ACTIVE MOIETY | YO7261ME24 | 4 | |
| gelatin | INACTIVE INGREDIENT | 2G86QN327L | 4 | |
| glycerin | INACTIVE INGREDIENT | PDC6A3C0OX | 4 | |
| mannitol | INACTIVE INGREDIENT | 3OWL53L36A | 4 | |
| polyethylene glycol 400 | INACTIVE INGREDIENT | B697894SGQ | 4 | |
| sodium hydroxide | INACTIVE INGREDIENT | 55X04QC32I | 4 | |
| sorbitan | INACTIVE INGREDIENT | 6O92ICV9RU | 4 | |
| sorbitol | INACTIVE INGREDIENT | 506T60A25R | 4 | |
| water | INACTIVE INGREDIENT | 059QF0KO0R | 4 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 50580-779 | 50580-779-12, 50580-779-25, 50580-779-40, 50580-779-65 |
Every source-derived ingredient row is available through these pages.
| Name | UNII | Kind |
|---|---|---|
| GELATIN, UNSPECIFIED | 2G86QN327L | IACT |
| GLYCERIN | PDC6A3C0OX | IACT |
| MANNITOL | 3OWL53L36A | IACT |
| POLYETHYLENE GLYCOL 400 | B697894SGQ | IACT |
| WATER | 059QF0KO0R | IACT |
| SODIUM HYDROXIDE | 55X04QC32I | IACT |
| SORBITAN | 6O92ICV9RU | IACT |
| SORBITOL | 506T60A25R | IACT |
| CETIRIZINE HYDROCHLORIDE | 64O047KTOA | ACTIB |
| Version | Effective date | Source | Hydrated |
|---|---|---|---|
| 14 | 2025-10-08 | monthly-update | 2026-06-03 17:37:58 |
| 13 | 2024-11-08 | full-release | 2026-06-01 00:35:37 |
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| sorbitol | SORBITOL | 506T60A25R | CREAM / TOPICAL | 36.8 %w/w | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, LYOPHILIZED, FOR SOLUTION / SUBCUTANEOUS | ADJ PH | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, CHEWABLE, EXTENDED RELEASE / ORAL | 616 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | GRANULE, FOR SUSPENSION / ORAL | ADJ PH | ||
| glycerin | GLYCERIN | PDC6A3C0OX | GEL / OPHTHALMIC | 0.88 %w/w | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SUSPENSION / SUBCUTANEOUS | ADJ PH | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET, EXTENDED RELEASE / ORAL | 60 mg | ||
| gelatin | GELATIN | 2G86QN327L | GUM, CHEWING / BUCCAL | 102 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / INFILTRATION | ADJ PH | ||
| sorbitol | SORBITOL | 506T60A25R | SOLUTION / ORAL | 29268 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, SOLUTION / PARENTERAL | ADJ PH | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, FOR SUSPENSION / ORAL | 7621 mg | ||
| sorbitol | SORBITOL | 506T60A25R | GUM, CHEWING / ORAL | 6168 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SPRAY / NASAL | ADJ PH | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET, FILM COATED / ORAL | 20 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SUSPENSION / AURICULAR (OTIC) | 0.05 %w/w | ||
| gelatin | GELATIN | 2G86QN327L | TABLET, CHEWABLE / ORAL | 24 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | ENEMA / RECTAL | 0.44 %v/v | ||
| mannitol | MANNITOL | 3OWL53L36A | INJECTION, SOLUTION / INTRAVENOUS | 15400 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOAP / TOPICAL | 0.76 %w/w | ||
| glycerin | GLYCERIN | PDC6A3C0OX | JELLY / TOPICAL | NA | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SOLUTION / INTRAVENOUS | 136.55 mg | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | INJECTION / INTRAMUSCULAR | 406 mg | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | INJECTION / INTRAVENOUS | 28216 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SPRAY, METERED / NASAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | FILM / BUCCAL | 0.09 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | FILM, EXTENDED RELEASE / TRANSDERMAL | 306.2 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | MOUTHWASH / BUCCAL | 2 mg/1ml | ||
| sorbitol | SORBITOL | 506T60A25R | INJECTION / INTRA-ARTICULAR | 45 %w/v | ||
| gelatin | GELATIN | 2G86QN327L | TABLET, COATED / ORAL | 42.12 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SYRUP / ORAL | 16734 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / RECTAL | NA | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | OINTMENT, AUGMENTED / TOPICAL | 0.11 %w/w | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / EXTRACORPOREAL | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | EMULSION / OPHTHALMIC | 0.02 %w/v | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION/ DROPS / OPHTHALMIC | ADJ PH | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | GEL / VAGINAL | 1250 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INFILTRATION | ADJ PH | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SUSPENSION / ORAL | 400 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | CAPSULE, LIQUID FILLED / ORAL | 1.5 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / INTRAVENOUS | 2.78 %w/v | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION, POWDER, FOR SUSPENSION / INTRAVENOUS | ADJ PH | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | SYRUP / ORAL | 740 mg | ||
| mannitol | MANNITOL | 3OWL53L36A | POWDER, FOR SUSPENSION / ORAL | 7093 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | SOLUTION / ORAL | 32400 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, EMULSION / INTRAVENOUS | 24100 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | INJECTION / INTRASPINAL | ADJ PH | ||
| mannitol | MANNITOL | 3OWL53L36A | SOLUTION, GEL FORMING, EXTENDED RELEASE / OPHTHALMIC | 4.35 %w/w | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | CREAM / VAGINAL | 0.19 %w/w | ||
| mannitol | MANNITOL | 3OWL53L36A | TABLET, DELAYED RELEASE / ORAL | 639 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | TABLET, ORALLY DISINTEGRATING / ORAL | 1 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | POWDER / INTRAVENOUS | ADJ PH | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION / INTRAMUSCULAR | 450 mg | ||
| gelatin | GELATIN | 2G86QN327L | PASTILLE / ORAL | 143 mg | ||
| sorbitol | SORBITOL | 506T60A25R | POWDER / ORAL | 36000 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | TABLET / PERIODONTAL | 0.53 mg | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | TABLET, DELAYED RELEASE / ORAL | 35 mg | ||
| sodium hydroxide | SODIUM HYDROXIDE | 55X04QC32I | SOLUTION / ORAL | 9120 mg | ||
| glycerin | GLYCERIN | PDC6A3C0OX | INJECTION, SOLUTION / INTRAMUSCULAR | 15 %w/v | ||
| polyethylene glycol 400 | POLYETHYLENE GLYCOL 400 | B697894SGQ | FILM, SOLUBLE / ORAL | 29 mg |
All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.
| Application-product | Trade name | Ingredient | Strength | Dosage form / route | TE codes | RLD / RS | Approval date |
|---|---|---|---|---|---|---|---|
| N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | CETIRIZINE HYDROCHLORIDE | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | |
| N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | CETIRIZINE HYDROCHLORIDE | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | |
| N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | CETIRIZINE HYDROCHLORIDE | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | |
| N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | CETIRIZINE HYDROCHLORIDE | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 |
Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.
| Captured | Edition | Application-product | Trade name | Strength | Dosage form / route | Product TE source text | RLD / RS | Approval date | Source SHA-256 |
|---|---|---|---|---|---|---|---|---|---|
| 2026-11-14 07:37:17 | 2026-10 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | d4dbc9d85df4… | |
| 2026-11-14 07:37:17 | 2026-10 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | d4dbc9d85df4… | |
| 2026-10-15 13:18:30 | 2026-09 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | c2088c7a36db… | |
| 2026-10-15 13:18:30 | 2026-09 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | c2088c7a36db… | |
| 2026-09-14 22:38:34 | 2026-08 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 84e616aacf4f… | |
| 2026-09-14 22:38:34 | 2026-08 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 84e616aacf4f… | |
| 2026-08-18 06:07:40 | 2026-07 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | caaa826d4ba7… | |
| 2026-08-18 06:07:40 | 2026-07 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | caaa826d4ba7… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 011fe1cb6892… | |
| 2026-02-19 14:30 UTC | 2026-02 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 011fe1cb6892… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 31067a03dcf5… | |
| 2025-12-14 10:44 UTC · 2 captures of this ZIP | 2025-12 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 31067a03dcf5… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 6a471c1ec25d… | |
| 2025-08-23 18:47 UTC | 2025-08 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 6a471c1ec25d… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | fd3edfee7708… | |
| 2025-03-22 03:13 UTC · 3 captures of this ZIP | 2025-03 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | fd3edfee7708… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | b8a1b40f171c… | |
| 2025-02-26 10:13 UTC · 3 captures of this ZIP | 2025-02 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | b8a1b40f171c… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022429-001 | CETIRIZINE HYDROCHLORIDE ALLERGY | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022429-002 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022429-003 | CETIRIZINE HYDROCHLORIDE HIVES RELIEF | 5MG | CAPSULE / ORAL | RLD | 2009-07-23 | 03ed91905a0d… | |
| 2025-01-19 17:59 UTC · 7 captures of this ZIP | 2025-01 | N022429-004 | CETIRIZINE HYDROCHLORIDE ALLERGY | 10MG | CAPSULE / ORAL | RLD, RS | 2009-07-23 | 03ed91905a0d… |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| 447a309e-7ad2-0dbe-e063-6394a90ab6fc | 605adf29-734f-451a-8ff3-74be7b5814a6 | 2025-11-26 | Warnings | 447a309e-7ad2-0dbe-e063-6394a90ab6fc 605adf29-734f-451a-8ff3-74be7b5814a6 |
Adverse event summaries are temporarily unavailable. Other product information remains available.